How Idiopathic Pulmonary Fibrosis Is Diagnosed and Slowed

Idiopathic pulmonary fibrosis (IPF) is diagnosed by matching the clinical picture against a specific pattern of lung scarring called usual interstitial pneumonia (UIP), identified on a high-resolution CT scan and confirmed through a structured multidisciplinary discussion rather than by any single blood test or biopsy. The 2022 ATS/ERS/JRS/ALAT clinical practice guideline allows a "probable UIP" CT pattern to support an IPF diagnosis without surgical biopsy in the right patient. There is no cure, but two antifibrotic drugs, pirfenidone and nintedanib, slow the disease: in their pivotal trials each roughly halved the yearly loss of forced vital capacity (FVC), the standard measure of how much air a person can exhale.

What IPF is, and why the pattern matters

IPF is a progressive fibrosing lung disease of unknown cause, usually in adults over 60, more common in men and in current or former smokers. Scar tissue replaces the delicate architecture where oxygen crosses into the blood, so the lungs stiffen and shrink. "Idiopathic" means no identifiable trigger, which makes it a diagnosis of exclusion: connective tissue disease, chronic hypersensitivity pneumonitis, drug toxicity, and occupational exposures all have to be ruled out first. That is why the label rests so heavily on a recognizable imaging pattern.

The four CT patterns

The 2022 guideline, published by Raghu and colleagues in the American Journal of Respiratory and Critical Care Medicine, sorts the high-resolution CT into one of four categories: UIP, probable UIP, indeterminate for UIP, and an alternative diagnosis. A definite UIP pattern shows scarring concentrated at the lung bases and periphery, with honeycombing (clustered cystic air spaces) and traction bronchiectasis. Probable UIP shows the same distribution and traction changes but without definite honeycombing. Indeterminate and alternative patterns point away from IPF and toward other causes.

The practical shift in recent guidance is what "probable UIP" now buys you. In the right clinical setting, for example an older former smoker with no evidence of another cause, a probable UIP scan can support a confident IPF diagnosis without tissue sampling. That spares many patients a surgical lung biopsy, a procedure with real risk in people whose lungs are already compromised.

Why the multidisciplinary discussion is the real test

No image is read in isolation. The guideline places the multidisciplinary discussion (MDD) at the center of diagnosis, bringing a pulmonologist, a chest radiologist, and a pathologist, and when relevant a rheumatologist, around the same case. This format improves diagnostic agreement, particularly for the hard cases where the CT is probable, indeterminate, or conflicts with the clinical story. The MDD is where incongruent data get reconciled, and where the decision to biopsy or not is actually made.

When tissue is needed, the guideline recognizes transbronchial lung cryobiopsy as an acceptable alternative to surgical biopsy in centers with proven expertise, and it addresses molecular tools such as a genomic classifier that can identify a UIP pattern from small samples. These options widen the path to a diagnosis without always resorting to the operating room.

What antifibrotic therapy actually does

Once IPF is established, the goal changes from confirming the disease to slowing it. Two oral antifibrotics carry the evidence. Neither reverses scarring or restores lost lung; both slow the rate at which FVC falls.

Pirfenidone was tested in the phase 3 ASCEND trial (King and colleagues, New England Journal of Medicine, 2014). Over 52 weeks, the mean decline in FVC was 235 mL on pirfenidone versus 428 mL on placebo, a relative reduction of about 45 percent, and the proportion of patients who lost 10 percentage points or more of predicted FVC or died fell by about 48 percent.

Nintedanib was tested in the twin INPULSIS trials (Richeldi and colleagues, New England Journal of Medicine, 2014). The adjusted annual FVC decline was about 115 mL per year with nintedanib versus roughly 210 to 240 mL per year with placebo across the two studies, a relative reduction of roughly half in each trial. The two drugs have not been shown to be clearly superior to one another, and both carry tolerability trade-offs, mainly gastrointestinal effects with nintedanib and nausea plus photosensitivity with pirfenidone.

Guideline recommendations for antifibrotic therapy in IPF are conditional, reflecting a real but partial benefit. The 2022 update also formalizes a separate category, progressive pulmonary fibrosis, for other fibrosing lung diseases that keep worsening despite treatment, where nintedanib is conditionally recommended as well.

What "slowing" means in practice

Halving a decline is not stopping it. A patient on an antifibrotic is still likely to lose lung function, just more slowly, which over years can translate into more time with usable breathing and, in pooled analyses, a signal toward longer survival. That framing matters because the honest promise of these drugs is measured in slope, not in reversal. Alongside the medicines, supplemental oxygen, pulmonary rehabilitation, vaccination, treatment of reflux and other coexisting conditions, and early conversations about lung transplant all shape how the disease is managed.

The larger point for anyone reading a scan report or a trial headline is that IPF diagnosis is a pattern-plus-context judgment, and its treatment is honest about buying time rather than promising a cure. This article is educational and not medical advice.